Cardiac surgery patients commonly present bleeding complications that negatively influence patient's clinical outcome. Therefore, fast and detailed diagnoses as well as early and specific therapy of perioperative coagulopathy are of high clinical relevance. The so-called point-of-care (POC) methods for coagulation analyses are increasingly used in perioperative care. It is the purpose of this review to present modern aspects of coagulation management, discuss the effect of the implementation of POC methods in perioperative care, and present substantial components of hemotherapy algorithms to manage coagulopathy in cardiac surgery patients.
INTRODUCTION
Patients undergoing cardiovascular surgery are at particular risk for the development of perioperative coagulopathy. In addition to coagulopathy, other independent risk factors that have an impact on postoperative morbidity and mortality include excessive blood loss, the use of allogeneic blood products, and reoperation for bleeding [1 & ,2]. Algorithm-based hemostatic therapy has been shown to be superior to empiric hemostatic therapy that is based on clinical judgment [3] . Thus, there is a clear need to improve algorithms of hemotherapy in the setting of cardiovascular surgery.
Efficient hemotherapy should treat the coagulopathy, prevent thromboembolic events, and reduce blood loss, thereby reducing transfusion requirements and risk of transfusion-related adverse events and save costs. These challenges highlight the need for an effective hemotherapy that necessitates both a specific hemotherapy algorithm, and the availability of point-of-care (POC) diagnostics to enable a fast and comprehensive diagnosis of the multifactorial causes of perioperative hemorrhage.
DIAGNOSIS OF COAGULOPATHY
Fast and comprehensive diagnoses of the underlying causes of perioperative coagulopathy are of elementary clinical relevance and represent a clinical challenge because particularly in cardiac surgery patients, the causes of coagulopathy are of multifactorial origin.
Multifactorial cause of coagulopathy
There are several surgery-related factors during cardiac surgery procedures that increase the risk of coagulopathy. These include the use of heparin to limit clotting during extracorporeal circulation, the dilution, activation and consumption of coagulation factors, and factors associated with the use of cardiopulmonary bypass machines, such as acquired platelet dysfunction, hypothermia, and hyperfibrinolysis. In addition to these surgery-related factors, the use of preoperative anticoagulation medication may also increase the likelihood of perioperative coagulopathy [4] .
Limitations of conventional laboratory coagulation analyses
The conventional laboratory coagulation analyses [international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count, fibrinogen concentration)] are of limited use for the prediction and detection of perioperative coagulopathies and for the monitoring of their treatment [5] . Analysis at a standardized temperature of 378C impedes the detection of coagulopathies induced by hypothermia. The global tests, aPTT and INR/ Quick, reflect only the initial formation of thrombin in plasma and are unaffected by any of the corpuscular elements of the blood. The platelet count is purely quantitative and cannot detect preexisting, drug-induced, or perioperatively acquired platelet dysfunction. Neither do the conventional coagulation tests convey any information about clot stability over time, nor do they provide information regarding fibrinolysis, and thus cannot detect hyperfibrinolysis. Usually, performing laboratory analyses and reporting coagulation test results take 40-90 min after blood drawing. As the coagulation system may undergo a very dynamic process, this turnaround time is so long that the results may not reflect the current state of the coagulation system and lead to inappropriate treatment [6] .
Point-of-care testing
The use of POC tests may partly compensate for the methodological limitations and diagnostic shortfalls of conventional coagulation testing. After a median turnaround time of 23 min (interquartile range 21-24 min), test results are available earlier as compared with conventional laboratory analyses [7 & ]. None of the currently available methods of POC coagulation testing can alone provide an adequate picture of the entire coagulation spectrum; thus, only various methods in conjunction may serve as a comprehensive diagnostic system. A combination of aggregometric and viscoelastic methods yields a marked broader diagnostic spectrum than the conventional laboratory testing of blood clotting. Aggregometric measures are used to screen for disorders of primary hemostasis, such as (acquired) platelet dysfunctions and allow the quantification of the effect of antiplatelet medications. Viscoelastic POC techniques are based on thromboelastography, which was described decades ago by Hartert [8] . They are used to measure the time until clot formation begins, the dynamics of clot formation, and the solidity and stability of clots over time. They enable parallel measurements to be performed on a single blood sample after clotting has been activated using a variety of agonists. A special advantage of viscoelastic techniques is that they can directly detect hyperfibrinolysis.
Implementation of point-of-care testing in perioperative care
Up to now, seven prospective randomized trials studied the effect of perioperative POC coagulation testing during cardiac surgery [3, [9] [10] [11] [12] [13] 14 && ]. All studies focused on potential differences in the transfusion requirements; four of them also analyzed perioperative blood loss as primary study endpoints [3, [11] [12] [13] . In five studies, solely viscoelastic tests were used, and in two studies [3,14 && ], viscoelastic and aggregometric tests were combined. In two studies patients also in the control group received hemotherapy according to a therapy algorithm [3, 14 && ], and in two studies, the authors exclusively focused on coagulopathic patients [11,14 && ]. All authors with the exception of Westbrook et al. [13] reported a POC-associated decrease in transfusion requirements. Reduced postoperative blood loss was observed in those two studies that only included coagulopathic patients [11,14 && ]. Improved clinical outcome (expressed as fewer rethoracotomies [11] or postoperative mechanical ventilation time, composite adverse events and shorter 6-month mortality [14 && ]) was also observed only in those two studies which included exclusively coagulopathic patients. A retrospective study including 3865 cardiac surgery patients who
KEY POINTS
Conventional laboratory coagulation analyses are inappropriate for guiding perioperative coagulation management.
Viscoelastic and aggregometric POC measures should be implemented in hemotherapy algorithms.
Specific isolated coagulation factor deficiencies should be corrected by factor concentrates.
The transfusion of FFP should be performed only in the clinical setting of massive transfusion.
Perioperative coagulation management Weber et al. 
HEMOTHERAPY ALGORITHM
Avidan et al. [3] showed that algorithm-based hemotherapy was superior to hemotherapy based on clinical judgment. Thus, perioperative coagulation management should be based on a hemotherapy algorithm that is implemented in institutional standard care. Each therapy should involve a preoperative assessment of the patient's individual bleeding risk, in particular considering preoperatively performed antiplatelet therapy. Intraoperative and postoperative coagulation management consists of frequent evaluation and correction of basic physiological conditions required for hemostasis and effective antagonism of heparin. When indicated, replacement of deficient coagulation factors and improving the hemostatic potential of the primary hemostasis are consecutive steps in therapy escalation. Ultima ratio options are off-label use of factor XIII and recombinant factor VIIa.
Evaluate patient's bleeding risk
The first step of any effective therapy algorithms should evaluate the patient's individual bleeding risk. This should be done by conducting a preoperative standardized questionnaire, which highlights any unusual bleeding in the patient's history, any hereditary coagulopathy, for example, von Willebrand disease and any anticoagulatory medication the patient is taking. There are almost no costs associated with such questionnaires and they can be effective in discovering preoperative factors that may contribute to coagulopathy.
Maintain optimal physiological conditions for hemostasis
During the perioperative period, anesthesiologists should frequently evaluate and if necessary correct basic physiologic conditions for hemostasis. The patient's physiological pH and core temperature should be maintained at more than 7.3 or 368C, respectively. Calcium is an elementary cofactor in several enzymatic processes during coagulation [16] . It is important to maintain a plasma-ionized calcium concentration of more than 1 mmol/l. With respect to the rheological properties of red blood cells and the provision of thromboxane A2 and ADP for platelet aggregation, we suggest that the hematocrit should be maintained at a concentration of more than 25% following extracorporeal circulation in coagulopathic patients.
Antagonize heparin
After cardiopulmonary bypass, protamine is used routinely to antagonize 100% of the initial heparin dose. However, in cases of ongoing bleeding, it is necessary to exclude any persistent heparin effects. If the activated clotting time remains more than 130 s, or viscoelastic measures indicate persistent heparin effects, it may be necessary to administer additional protamine (30 IU/kg) and to re-evaluate its therapeutic effect.
Maintain adequate levels of coagulation factors
If coagulopathy persists following reversal of the anticoagulant effects of heparin, it should be ensured that adequate levels of coagulation factors are maintained. Fibrinogen is the first coagulation factor to fall below lower reference values during bleeding [17] . As the precursor to fibrin, and as a ligand for platelet aggregation, fibrinogen plays a key role in clot formation [18] . Thus, if plasma levels of fibrinogen drop below 150-200 mg/dl, or if viscoelastic tests indicate a deficiency, it is necessary to administer a fibrinogen substitute. In the past, fresh frozen plasma (FFP; 15-30 ml/kg) has been used as a source of replacement fibrinogen. However, the transfusion of FFP is associated under certain conditions with volume overload, sepsis, multiple organ failures, and increased perioperative mortality [19, 20] . An alternative source of fibrinogen is fibrinogen concentrate, which should be used at a concentration of 25-50 mg/kg. A recent review of trials in which fibrinogen concentrate was used in perioperative settings or in cases of massive hemorrhage suggests that this form of substitution is both effective and well tolerated [21 & ]. If coagulopathy persists following supplementation of fibrinogen, the next stage of the therapy algorithm should be to analyze and -if necessarycorrect a potential deficiency of prothrombin complex coagulation factors II, VII, IX, and X. Substitution of factors II, VII, IX, and X should be considered if the INR is more than 1.4, or if viscoelastic measures reveal a deficiency. A dosage of 15-30 ml/kg FFP is necessary to increase the concentration of these factors. However, the use of a prothrombin complex concentrate, which depending on the product contains factors II, VII, IX, and X, proteins C and S, heparin, and antithrombin, represents an attractive alternative due to the much smaller volumes required to supplement the deficiency (recommended dose 20-30 IU/kg) [22] .
Platelets
After the substitution of coagulation factors, the therapy algorithm should lead to a consideration of both platelet count and function. Importantly, temperature has a strong impact on platelet function [23] . In addition to temperature, the use of extracorporeal circulation negatively impacts on primary hemostasis [24] . Extracorporeal circulation causes irreversible platelet damage mainly due to mechanical defragmentation and reduction of platelet surface glycoproteins (GPIb and GPIIb/IIIa), which are important for platelet adhesion and aggregation. Extent surface contact during extracorporeal circulation causes significant platelet dysfunctions [25] .
Conventional laboratory analyses are of limited informative value as they only provide a quantitative measure of platelet numbers without providing any information regarding platelet functionality. In contrast, aggregometric measures allow the assessment of platelet function by measuring the amount of platelet aggregation induced in the presence of common platelet agonists such as thrombin, arachidonic acid, ADP, epinephrine, or collagen. Results of aggregometric measures allow monitoring of the effects of preoperatively performed antiplatelet therapy as well as analyzing the extent of intraoperative acquired platelet dysfunctions [26] .
If platelet function has been proven to be deficient, the administration of desamino-Darginine vasopressin (DDAVP) represents a therapy option. DDAVP (0.3 mg/kg) has been shown to induce a three-fold increase in von Willebrand factor and factor VIII [27] . These factors promote an increase in platelet-endothelial cell adhesion via the GPIb receptor and platelet-platelet aggregation via the GPIIb/IIIa receptor. A further option to increase the hemostatic potential of the primary hemostasis is to transfuse platelet concentrates. In general, transfusion of one unit of platelet concentrate will increase the platelet count by approximately 30 000 per ml. However, there are inherent risks associated with the transfusion of platelet concentrates, in particular, the risk of transmission of bacterial and/or viral infections. Additionally, the number and functionality of platelets in platelet concentrates decreases in dependency of storage time [28] [29] [30] .
Ultima ratio
If coagulopathy persists and surgical causes for bleeding have been ruled out, off-label usage of two additional coagulation factor concentrates, factor XIII and activated factor VII, represents an 'ultima ratio' therapy approach. Factor XIII enhances blood clot stability by cross-linking fibrin monomers and integrating a2 antiplasmin into developing clots. There is no routinely available test parameter that may indicate a factor XIII deficiency. In addition, there are currently no standardized reference values. However, on the basis of the clinical experience, the authors recommend using 1250-2500 units of coagulation factor XIII as a single shot infusion.
Administration of recombinant factor VIIa (90 mg/kg) induces a so-called 'thrombin burst'. As the final stage of the therapy algorithm, it may potentially reverse life-threatening coagulopathy. However, several preconditions such as plasma pH 7.2 or more, fibrinogen concentration more than 150 mg/dl, platelet count more than 50 000 per ml, hematocrit 25% or more, ionized calcium concentration more than 1 mmol/l, and body temperature more than 368C should be met before factor VIIa is administered. However, as highlighted in a recent systematic review, the effectiveness of recombinant factor VIIa in reducing the transfusion rate of allogeneic blood products or the perioperative blood loss remains unproven [31] .
CONCLUSION
Viscoelastic and aggregometric methods should be implemented in perioperative care. They provide a detailed analysis of perioperative hemorrhage and allow an early, goal-directed, and efficient hemotherapy. Implementation of POC methods in hemotherapy algorithms reduces the transfusion rate of allogenic blood products and may beneficially influence patient's clinical outcome.
Hemotherapy should be based on a hemotherapy algorithm consisting of consecutive steps of therapy escalation with special regard to preoperatively performed anticoagulatory therapy.
